Evidence map›Paper›PMID 36676797›Full record

ReviewMedicina (Kaunas, Lithuania)2023

MicroRNAs: Small Molecules with Significant Functions, Particularly in the Context of Viral Hepatitis B and C Infection.

Fayed Megahed, Ashraf Tabll, Shimaa Atta, Ameera Ragheb, Robert Smolic, Ana Petrovic, Martina Smolic

Open access · goldAbstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Regulation of humeral fracture healing by miR-21 through SMAD7-mediated activation of Wnt/β-catenin signaling.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  2. Article
  3. Hepatitis B Virus and microRNAs: A Bioinformatics Approach.International journal of molecular sciences · 2023
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Fayed MegahedNucleic Acid Research Department, Genetic Engineering and Biotechnological Research Institute (GEBRI), City for Scientific Researches and Technological Applications (SRTA-City), Alexandria 21934, Egypt.
Ashraf TabllMicrobial Biotechnology Department, National Research Centre, Giza 12622, Egypt.ORCID 0000-0001-7041-5445
Shimaa AttaDepartment of Immunology, Theodor Bilharz Research Institute, Cairo 12411, Egypt.
Ameera RaghebEgypt Center for Research and Regenerative Medicine (ECRRM), Cairo 11517, Egypt.
Robert SmolicFaculty of Dental Medicine and Health Osijek, University of Osijek, Crkvena 21, 31000 Osijek, Croatia.
Ana PetrovicFaculty of Dental Medicine and Health Osijek, University of Osijek, Crkvena 21, 31000 Osijek, Croatia.
Martina SmolicFaculty of Dental Medicine and Health Osijek, University of Osijek, Crkvena 21, 31000 Osijek, Croatia.ORCID 0000-0002-6867-826X
University of Osijek · HREgypt Center for Research and Regenerative Medicine · EGCity of Scientific Research and Technological Applications · EGTheodor Bilharz Research Institute · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A MicroRNA (miRNA) is defined as a small molecule of non-coding RNA (ncRNA). Its molecular size is about 20 nucleotides (nt), and it acts on gene expression's regulation at the post-transcription level through binding to the 3'untranslated regions (UTR), coding sequences, or 5'UTR of the target messenger RNAs (mRNAs), which leads to the suppression or degradation of the mRNA. In recent years, a huge evolution has identified the origin and function of miRNAs, focusing on their important effects in research and clinical applications. For example, microRNAs are key players in HCV infection and have important host cellular factors required for HCV replication and cell growth. Altered expression of miRNAs affects the pathogenicity associated with HCV infection through regulating different signaling pathways that control HCV/immunity interactions, proliferation, and cell death. On the other hand, circulating miRNAs can be used as novel biomarkers and diagnostic tools for HCV pathogenesis and early therapeutic response. Moreover, microRNAs (miRNA) have been involved in hepatitis B virus (HBV) gene expression and advanced antiviral discovery. They regulate HBV/HCV replication and pathogenesis with different pathways involving facilitation, inhibition, activation of the immune system (innate and adaptive), and epigenetic modifications. In this short review, we will discuss how microRNAs can be used as prognostic, diagnostic, and therapeutic tools, especially for chronic hepatitis viruses (HBV and HCV), as well as how they could be used as new biomarkers during infection and advanced treatment.

Indexed as

Hepatitis BHepatitis CMicroRNAsBiomarkersHepatitis B virusHumansBiomarkersMicroRNAsbiomarkersdiagnosishepatitis B virushepatitis C virusmicroRNAs

Identifiers

PMID36676797
PMCPMC9862007
OpenAlexW4316465967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.